Figure 3:

(A) In vitro release profile of DTX from the experimental formulation (L-DTX), marketed formulation (Taxotere®) and free-DTX solution in phosphate buffer, pH 7.4. Data show mean ± standard deviation of three different experiments in triplicate. (B) Cell viability study by MTT assay of blank formulation (B-DTX), L-DTX (formulation with DTX), marketed preparation (Taxotere®) and free-drug (DTX) in C6 glioma cells of rats. Data show mean ± standard deviation of three different experiments. (C) Cellular localization study of FITC-L-DTX (F-DTX) at different time points by fluorescence microscopy in C6 glioma cells of rats and (D) Flow cytometric measurement of C6 glioma cells of rats incubated with F-DTX at 0.5 h and 6 h of treatments, indicating about 18%, and about 23% enhancement of uptake in terms of FITC incorporated liposomes in cells at 0.5 h (Figure 3D-II) and 6 h (Figure 3D-III) of treatments, respectively, in comparison to untreated cells (Figure 3D-I).